We are live on ! Find out more
CC

Commodore Capital Portfolio holdings

AUM $1.73B
1-Year Est. Return 298.96%
This Fund
S&P 500
This Quarter Est. Return
+63.8%
1 Year Est. Return
+298.96%
3 Year Est. Return
+2,048.53%
5 Year Est. Return
+6,668.48%
10 Year Est. Return
–
AUM
$1.5B
AUM Growth
-$546M
Cap. Flow
-$1.03B
Cap. Flow %
-68.8%
Top 10 Hldgs %
55.82%
Holding
43
New
6
Increased
4
Reduced
12
Closed
10

Top Buys

Rank Stock Value
1
ANRO icon
Alto Neuroscience
ANRO
+$23M
2
PALI icon
Palisade Bio
PALI
+$22M
3
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$21.4M
4
ALKS icon
Alkermes
ALKS
+$13.6M
5
REPL icon
Replimune Group
REPL
+$12.1M

Top Sells

Rank Stock Value
1
MRUS
Merus
MRUS
+$332M
2
COGT icon
Cogent Biosciences
COGT
+$142M
3
TERN
Terns Pharmaceuticals
TERN
+$97.6M
4
AGIO icon
Agios Pharmaceuticals
AGIO
+$93.9M
5
NUVL
Nuvalent
NUVL
+$83.8M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RLAY icon
1
Relay Therapeutics
RLAY
$4.02B
$144M 9.57%
17,000,000
– –
ALKS icon
2
Alkermes
ALKS
$8.82B
$99.3M 6.61%
3,550,000
+453,246
+15% +$13.6M
TYRA icon
3
Tyra Biosciences
TYRA
$1.82B
$88.7M 5.91%
3,375,000
– –
XENE icon
4
Xenon Pharmaceuticals
XENE
$6.32B
$80.7M 5.37%
1,800,000
-900,000
-33% -$37.8M
SYRE icon
5
Spyre Therapeutics
SYRE
$8.87B
$78.2M 5.21%
2,388,245
+400,161
+20% +$10.5M
COGT icon
6
Cogent Biosciences
COGT
$6.79B
$78M 5.19%
2,196,845
-5,053,155
-70% -$142M
ELVN icon
7
Enliven Therapeutics
ELVN
$3.78B
$72.3M 4.81%
4,692,809
– –
CLDX icon
8
Celldex Therapeutics
CLDX
$2.77B
$69.7M 4.64%
2,565,000
-463,335
-15% -$12.2M
AMLX icon
9
Amylyx Pharmaceuticals
AMLX
$2.05B
$68.3M 4.54%
5,650,000
+1,574,522
+39% +$21.4M
TERN
10
DELISTED
Terns Pharmaceuticals
TERN
$59.6M 3.97%
1,475,000
-4,225,000
-74% -$97.6M
KYMR icon
11
Kymera Therapeutics
KYMR
$9.1B
$58.4M 3.88%
750,000
– –
SLNO
12
DELISTED
Soleno Therapeutics
SLNO
$55.6M 3.7%
1,200,000
-150,000
-11% -$8.22M
NUVL
13
DELISTED
Nuvalent
NUVL
$55.3M 3.68%
550,000
-850,000
-61% -$83.8M
ORKA
14
Oruka Therapeutics
ORKA
$5.56B
$53.1M 3.54%
1,753,054
– –
PHVS icon
15
Pharvaris
PHVS
$2.39B
$52.4M 3.49%
1,889,445
-529,031
-22% -$12.7M
NRIX icon
16
Nurix Therapeutics
NRIX
$2.43B
$43.2M 2.87%
2,275,000
-1,505,055
-40% -$21.6M
PTGX icon
17
Protagonist Therapeutics
PTGX
$8.75B
$39.3M 2.62%
450,000
-575,000
-56% -$47.1M
ASMB icon
18
Assembly Biosciences
ASMB
$506M
$34M 2.26%
1,000,000
– –
LBRX
19
LB Pharmaceuticals
LBRX
$1B
$33.4M 2.22%
1,500,000
– –
CTMX icon
20
CytomX Therapeutics
CTMX
$705M
$32.8M 2.18%
7,692,300
– –
ANRO icon
21
Alto Neuroscience
ANRO
$1.04B
$32.5M 2.16%
+1,823,196
New +$23M
PALI icon
22
Palisade Bio
PALI
$339M
$26.9M 1.79%
+11,445,000
New +$22M
DFTX
23
Definium Therapeutics
DFTX
$5.73B
$26.8M 1.78%
2,000,000
-1,225,000
-38% -$15.2M
CNTA
24
DELISTED
Centessa Pharmaceuticals
CNTA
$25M 1.66%
1,000,000
-1,850,000
-65% -$46.9M
PEPG icon
25
PepGen
PEPG
$133M
$22.1M 1.47%
3,400,000
+1,042,681
+44% +$5.41M
1
2

Similar funds

RIA
Regal Investment Advisors Kentwood, Michigan $1.73B AUM 17.74% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return
MCWS
McKinley Carter Wealth Services Wheeling, West Virginia $1.73B AUM 17.28% 1-Year Est. Return
VCA
Verdence Capital Advisors Hunt Valley, Maryland $1.72B AUM 24.88% 1-Year Est. Return
ESBC
E.S. Barr & Co Lexington, Kentucky $1.72B AUM 12.69% 1-Year Est. Return
MSR
Main Street Research Lakeville, Connecticut $1.72B AUM 48.78% 1-Year Est. Return
WJA
Willis Johnson & Associates Houston, Texas $1.72B AUM 16.93% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

Commodore Capital's Q4 2025 Portfolio in Review

As of Q4 2025, Commodore Capital held 43 positions worth $1.5B, down 27% from $2.05B the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Commodore Capital withdrew a net $1.03B in Q4 2025, closing 10 positions and reducing 12 holdings. Its most notable exit was Merus, an estimated $332M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

Against the trend, Commodore Capital opened a new position in Alto Neuroscience worth $32.5M.

  • Commodore Capital's largest Q4 2025 buy was Alto Neuroscience: 1,823,196 shares worth $32.5M.
  • Commodore Capital added most to Amylyx Pharmaceuticals in Q4 2025, an estimated $21.4M increase.
  • Commodore Capital's biggest Q4 2025 reduction was Cogent Biosciences, cutting an estimated $142M.
  • Commodore Capital fully exited Merus in Q4 2025, selling an estimated $332M.
  • Commodore Capital's ten largest holdings make up 56% of its $1.5B portfolio in Q4 2025.
  • Commodore Capital opened 6 new positions and closed 10 in Q4 2025.
  • Commodore Capital's portfolio value fell 27% quarter-over-quarter to $1.5B.

Based on Commodore Capital's 13F filing for Q4 2025, filed 17 Feb 2026.